

1 **Title Page**

2 **Vitamin D deficiency and toxicity across 2018 to 2022 in several cities of**  
3 **Ecuador: interrupted time series and a cross-sectional study**

4 **Short Title:** Vitamin D deficiency and toxicity across 2018 to 2022 in several cities  
5 of Ecuador

6 **Authors:**

7 Camilo Zurita-Salinas<sup>a,b</sup> , Betzabé Tello<sup>c,d</sup> , Iván Dueñas-Espín<sup>e</sup> , Jeannete  
8 Zurita<sup>a,c</sup>, William Acosta<sup>c</sup> , Cristina Aguilera León<sup>a</sup>, Andrés Andrade-Muñoz<sup>c</sup> , José  
9 Pareja-Maldonado<sup>c</sup>.

10 <sup>a</sup> Biomedical Research Unit. Zurita & Zurita Laboratories, Quito, Ecuador.

11 <sup>b</sup> Facultad de Ciencias Médicas. Universidad Central del Ecuador, Quito, Ecuador.

12 <sup>c</sup> Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito,  
13 Ecuador.

14 <sup>d</sup> Centro de Investigación para la Salud en América Latina CISEAL, Quito,  
15 Ecuador.

16 <sup>e</sup> Instituto de Salud Pública. Pontificia Universidad Católica del Ecuador, Quito,  
17 Ecuador.

18 **\* Corresponding author**

19 Betzabé Tello, Centro de Investigación para la Salud en América Latina CISEAL,  
20 Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito, Ecuador,  
21 Av. 12 de octubre 1076 and Roca, postal code: 170525, phone number: (593) (02)  
22 2991700 Ext 2881, Quito – Ecuador; e-mail: [bmtello@puce.edu.ec](mailto:bmtello@puce.edu.ec)

23

24 **Abstract**

25 **Objectives:** to identify differences in mean vitamin D concentrations in samples  
26 obtained from a private laboratory in the city of Quito, and to explore their  
27 relationship with the pre-pandemic and pandemic periods spanning from 2018 to  
28 2022.

29 **Design:** A combination of an interrupted time series design and a retrospective  
30 cross-sectional approach

31 **Setting and participants:** The study involved 9,285 participants who had their 25-  
32 hydroxyvitamin D (25(OH)D) levels tested at a well-known private laboratory in  
33 Quito, Ecuador, from 2018 to 2022.

34 **Primary and secondary outcome measures:** The 25(OH)D levels were analyzed  
35 and assessed for correlations with both age and the year in which the  
36 measurements were taken.

37 **Results:** The mean 25-hydroxyvitamin D (25(OH)D) level was 27.53 ng/mL ( $\pm$   
38 14.11). Approximately 64.58% of participants had insufficient levels, below 20  
39 ng/mL, and 0.62% showed potential harm from excess 25(OH)D, with levels over  
40 100 ng/mL. The analysis indicated a significant monthly increase of 0.133 units in  
41 25(OH)D levels ( $p=0.006$ ). However, the period after March 2020, compared to  
42 before, saw a non-significant decrease of 1.605 units in mean 25(OH)D levels  
43 ( $p=0.477$ ).

44 **Conclusions:** The study's findings indicate a significant prevalence of 25-  
45 hydroxyvitamin D (25(OH)D) deficiency, underscoring the necessity for  
46 preventative measures. Nevertheless, the rise in cases of vitamin D toxicity is  
47 concerning, emphasizing the importance of prudent vitamin D supplement  
48 prescriptions and public education against self-medication. For efficient resource  
49 allocation and targeting those with higher risks, it may be advantageous to  
50 concentrate vitamin D testing on specific population groups.

51

52 **Keywords:** 25-hydroxyvitamin-D; vitamin D deficiency; vitamin d toxicity,  
53 hypervitaminosis d, overdose.

## 54 **Introduction**

55 Vitamin D, a prohormone, has a crucial influence on a multitude of biological  
56 processes, encompassing immunological responses, phosphocalcic metabolism,  
57 and detoxification. Recent revelations regarding the diverse functions of vitamin D  
58 have engendered escalating interest among the scientific community, fostering an  
59 ongoing commitment to further research in this realm. The intricate regulation of  
60 vitamin D is governed by a complex interplay of genetic and environmental factors,  
61 underscoring the multifaceted nature of its mechanisms [1].

62 The primary source of vitamin D in humans stems from the interaction of UVB  
63 radiation with the skin during sunlight exposure. When the skin is exposed to  
64 ultraviolet radiation, a photochemical reaction occurs; cleaving carbon bonds in the  
65 precursor of vitamin D, 7-dehydrocholesterol, to form pre-vitamin D<sub>2</sub>. Subsequent  
66 temperature-dependent molecular rearrangements facilitate the production of  
67 active vitamin D, which can be stored within the body for several months due to its  
68 liposoluble nature[2]. In addition to sunlight, vitamin D can also be obtained from  
69 external sources such as certain foods and supplements[1].

70 Defining the optimal level of 25(OH)D, the major circulating form of vitamin D,  
71 remains a topic of ongoing debate[3]. Some studies have highlighted a potential  
72 overestimation of vitamin D deficiency prevalence in the population, fueling  
73 controversy over the necessity of supplementation in healthy individuals[3].  
74 Notably, The Endocrine Society defines deficiency as <20 ng/ml, insufficiency as  
75 21-29 ng/ml, and optimal levels as >30 ng/ml, while the Institute of Medicine  
76 (Health and Medicine Division of the National Academies) considers deficiency as  
77 <12 ng/ml, insufficiency as 12-20 ng/ml, and optimal levels as >20 ng/ml.  
78 Furthermore, The American Association of Clinical Endocrinologists defines  
79 deficiency as < 30 ng/ml and optimal levels as 30-50 ng/ml[4]. Globally, an  
80 estimated 15.7% of the population suffers from a vitamin D deficit, with South  
81 America exhibiting a higher prevalence of 34.75%[4,5]. No previous studies in  
82 Ecuador have considered altitude and the pandemic. Quito, Ecuador's capital, sits  
83 at 2850 meters above sea level.

84 During the COVID-19 pandemic, several studies have documented significant  
85 lifestyle changes among individuals, including modifications in dietary patterns,  
86 reduced participation in outdoor activities, and a decline in physical exercise[6].  
87 These lifestyle shifts have the potential to impact vitamin D synthesis, as they may  
88 serve as contributing factors[6,7].

89 Vitamin D deficiency has been linked to acute and chronic diseases that affect not  
90 only the skeletal system but also other physiological systems. Timely treatment for  
91 individuals with vitamin D deficiency can potentially improve their quality of life and  
92 reduce associated health risks[8].

93 The objective of this study was to identify differences in mean vitamin D  
94 concentrations in samples obtained from a private laboratory in the city of Quito,  
95 and to explore their relationship with the pre-pandemic and pandemic periods  
96 spanning from 2018 to 2022.

## 97 **Methods**

### 98 *Design*

99 A combination of an interrupted time series design and a retrospective cross-  
100 sectional approach was employed in this study to assess shifts in population-level  
101 25-hydroxyvitamin D (25(OH)D) status and associated toxicity in Ecuador, pre -  
102 and post-onset of the COVID-19 pandemic. Data were collated at multiple time  
103 points through cross-sectional measures of previously collected data prior to and  
104 following the pandemic's onset. This design facilitated the appraisal of long-term  
105 trends and the potential influence of the pandemic on 25-hydroxyvitamin D  
106 (25(OH)D) levels and associated toxicity.

### 107 *Settings*

108 This study was conducted primarily in a large private laboratory in Quito, Ecuador.  
109 A diverse cohort of patients was included, most of whom had their 25-  
110 hydroxyvitamin D (25(OH)D) levels tested at the request of their physicians. These  
111 people came from various cities, primarily from Quito, Ibarra, Ambato, and Santo

112 Domingo. Data from 2018 to 2022 were analyzed, with the exception that for the  
113 year 2022 only data from January were included.

#### 114 *Study population and sample size*

115 The study population comprised people who had their 25-hydroxyvitamin D  
116 (25(OH)D) levels tested at a large private laboratory in Quito, Ecuador, between  
117 the years 2018 and 2022. A vast majority of these tests were performed at the  
118 request of the patients' physicians. Patients from various cities such as Quito,  
119 Ambato, Ibarra, and Santo Domingo contributed to the diversity of the sample. The  
120 total sample size was 9,285. By the year 2022, the sample included only those  
121 people whose vitamin D levels were tested in January. Additionally, we performed  
122 a secondary analysis in a subsample of 919 patients in which we collected  
123 information about chronic diseases and medications in order to calculate the  
124 prevalence of inadequate levels of vitamin D in people with and without chronic  
125 diseases.

#### 126 *Data collection procedures*

127 There is a consensus among experts regarding the use of serum/plasma 25(OH)D  
128 concentration as the preferred method to evaluate vitamin D status. It is widely  
129 agreed that this measurement reflects the combined contributions of diet and  
130 dermal synthesis. The choice of 25(OH)D is justified by its advantageous  
131 characteristics, including its extended half-life of 15 days, relative stability,  
132 abundant presence in the blood, and responsiveness to recent endogenous  
133 vitamin D production and exogenous intake from diet or supplements[1,9]. The  
134 determination of 25-hydroxyvitamin D Total in human plasma was assessed using  
135 the ELFA (Enzyme Linked Fluorescent Assay) technique. The measurements were  
136 performed using the VIDAS laboratory machine, employing reagents manufactured  
137 by Biomerieux. Following the completion of the assay, the results were  
138 automatically analyzed by the computer.

139 The instrument automatically calculated the results using stored calibration curves  
140 based on a 4-parameter logistics model. The results were expressed in either  
141 ng/mL or nmol/L.

142 The VIDAS 25 OH Vitamin D TOTAL measurement range spanned from 8.1 ng/mL  
143 to 126.0 ng/mL. Results below the lower limit of the measurement range were  
144 reported as "< 8.1 ng/mL," while values above the upper limit were reported as ">  
145 126.0 ng/mL.". In this study, the reference value of < 20ng/mL was adopted to  
146 classify laboratory samples as "inadequate levels", encompassing values indicating  
147 deficiency and insufficiency. Furthermore, values exceeding 100 ng/mL were  
148 considered "suggestive toxicity".

#### 149 *Variables*

150 The main variables of interest in this study were serum concentrations of  
151 25-hydroxyvitamin D [25(OH)D], age, and the year of measurement. Vitamin D  
152 levels were classified as 'deficiency', 'insufficient' and 'sufficient' based on  
153 recognized clinical thresholds. We further classified "Suggestive toxicity" when the  
154 values were >100 ng/mL, and "Inadequate levels" when the values were deficient  
155 or insufficient. Age was stratified into four categories: 'Children and adolescents',  
156 'Young adults', 'Middle-aged adults' and 'Older adults'. The year of measurement  
157 was used to compare vitamin D levels before and after the start of the COVID-19  
158 pandemic. We also considered two outcome variables: 'Suggestive toxicity' and  
159 'Inadequate levels'.

#### 160 *Statistical analysis*

161 Descriptive statistics were first calculated to summarize the basic characteristics of  
162 the data set, including means and standard deviations for continuous variables,  
163 and frequencies and percentages for categorical variables. We stratified the  
164 analyzes by age group and by year of measurement to assess temporal trends in  
165 25-hydroxyvitamin D (25(OH)D) levels. Chi-square tests were used to examine  
166 differences in the distribution of categorical variables between different groups. For  
167 continuous variables, independent samples t tests or Mann-Whitney U tests were

168 used, as appropriate. A p-value of less than 0.05 was considered statistically  
169 significant. To further explore the relationships between age, year of measurement,  
170 and 25-hydroxyvitamin D (25(OH)D) levels, cross-tabulations were performed.  
171 These analyzes were used to identify the prevalence of 25-hydroxyvitamin D  
172 (25(OH)D) deficiency, insufficiency, sufficiency, suggestive toxicity, and inadequate  
173 levels within each age group and year. Results are reported as mean  $\pm$  standard  
174 deviation (SD) for continuous variables and number (percent) for categorical  
175 variables, unless otherwise stated.

176 Two secondary analyses were performed: First, within a subsample of participants  
177 to investigate possible selection bias in the study results. The association between  
178 self-reported illnesses and inadequate 25-hydroxyvitamin D (25(OH)D) levels was  
179 assessed using a chi-square test. Medical conditions were self-reported using the  
180 personal data form, and this information was integrated into the laboratory's  
181 database, along with data on medication use and comorbidities. Second, a  
182 secondary analysis was performed to compare 25-hydroxyvitamin D (25(OH)D)  
183 levels between cities located at different altitudes: Quito, Ambato, and Ibarra,  
184 located above 2,500 masl, and Santo Domingo, located below 625 masl. The chi-  
185 square test was used to examine the association between city location and  
186 inadequate vitamin D levels.

187 To examine the potential change in average 25-hydroxyvitamin D (25(OH)D)  
188 concentration before and after March 2020 (pre-pandemic and pandemic periods),  
189 a multiple linear regression analysis was employed. The independent variables in  
190 the analysis included the passage of time (measured in months), a binary variable  
191 indicating the period after March 2020, and an interaction term combining these  
192 two variables. The dependent variable was the average monthly 25-hydroxyvitamin  
193 D (25(OH)D) concentration. The total sample size for the regression analysis was  
194 49.

195 For the statistical analysis, a Poisson regression model was utilized to determine  
196 the prevalence ratios for two health outcomes, namely toxicity and inadequate  
197 levels of 25-hydroxyvitamin D (25(OH)D), over a four-year period (2018-2021). For



198 each outcome, the year of observation was included as a categorical independent  
199 variable, and prevalence ratios were estimated in relation to the base year of 2018.  
200 Observations from the year 2022 were excluded from the analysis.

201 All statistical analyzes were performed using Stata 15.1 (Stata Corp. 2015. Stata  
202 Statistical Software: Release 14. College Station, TX: StataCorp LP). A  
203 significance level of  $p < 0.05$  was considered statistically significant, indicating the  
204 presence of significant differences between the groups.

### 205 *Ethical issues*

206 The study protocol (CEISH 659-2022) received ethical approval from the Ethics  
207 Committee for Research in Human Beings of the Pontifical Catholic University of  
208 Ecuador, following an expedited review process.

## 209 **Results**

210 Descriptive results from the total sample are shown in **Table 1**. In this study  
211 population of  $n=9286$ , most participants were female (74.65%). The mean age of  
212 the population was 51.58 years ( $\pm 23.00$ ), and the age range varied from 1-2 years  
213 to 100-130 years. The mean concentration of 25-hydroxyvitamin D (25(OH)D) was  
214 27.53 ng/mL ( $\pm 14.11$ ). Regarding 25-hydroxyvitamin D (25(OH)D) levels, 64.58%  
215 of the participants had inadequate levels, defined as a concentration of 25-  
216 hydroxyvitamin D (25(OH)D) below 20 ng/mL. In addition, suggestive toxicity,  
217 indicating potential harm due to excess 25-hydroxyvitamin D (25(OH)D), was  
218 present in 0.62% of the population, with a 25(OH)D concentration limit greater than  
219 100 ng/mL. There was missing information because some participants did not  
220 provide their sex. The presented means and standard deviations provide more  
221 information about the age distribution and 25-hydroxyvitamin D (25(OH)D)  
222 concentration within the study population.

223 **Table 1: Demographics, 25-hydroxyvitamin D (25(OH)D) Levels, and Inadequate and**  
224 **Suggestive Toxicity of 25-hydroxyvitamin D (25(OH)D) of the Study Population**  
225 **(N=9286)**



Variable	Statistics
<b>Sex</b>	
Female, n (%)	6932 (74.65%)
Male, n (%)	2318 (24.96%)
Not registered, n (%)	36 (0.39%)
<b>Mean Age (<math>\pm</math> SD)</b>	51.58 years ( $\pm$ 23.00)
<b>Age Range (Years)</b>	
1-2, n (%)	34 (0.37%)
3-5, n (%)	93 (1.01%)
6-11, n (%)	275 (2.98%)
12-17, n (%)	440 (4.76%)
18-65, n (%)	5630 (60.92%)
66-79, n (%)	1685 (18.23%)
80-99, n (%)	1070 (11.58%)
100-130, n (%)	14 (0.15%)
<b>Mean 25-hydroxyvitamin D (25(OH)D) Concentration (<math>\pm</math> SD)</b>	27.53 ng/mL ( $\pm$ 14.11)
<b>Inadequate 25-hydroxyvitamin D (25(OH)D) Level</b>	
Yes, n (%)	5997 (64.58%)
<b>Suggestive Toxicity</b>	
Yes, n (%)	58 (0.62%)
<i>Notes:</i>	
1. <i>Inadequate 25-hydroxyvitamin D (25(OH)D) Level</i> was defined as having a concentration of 25-hydroxyvitamin D (25(OH)D) less than 20 ng/mL.	
2. <i>Suggestive Toxicity</i> was defined based on the presence of symptoms indicating potential harm or risk due to excess 25-hydroxyvitamin D (25(OH)D), as ascertained by medical evaluation, and when the concentration of 25-hydroxyvitamin D (25(OH)D) exceeded 100 ng/mL.	
3. Participants who did not disclose their gender are listed as 'Not Disclosed' under the 'Sex' category.	
4. Age is categorized into ranges for easier data interpretation.	
5. The means for age and 25-hydroxyvitamin D (25(OH)D) concentration are presented with their respective standard deviations.	

226


227 Additionally, regarding the two secondary analyses, First, in the subsample  
 228 analysis, no significant differences were found in inadequate 25-hydroxyvitamin D

229 (25(OH)D) levels between those without self-reported diseases (63%), those  
230 without any medication (64%), those with any self-reported disease (64%), and  
231 those taking any medication (61%) (**S1 Table**). Inadequate levels were considered  
232 based on specific criteria related to Vitamin D status. These findings suggest that  
233 the results of our study are more generalizable to the general population from  
234 which the sample was drawn, since there does not seem to be a selection bias  
235 related to the presence of diseases. Furthermore, when comparing 25-  
236 hydroxyvitamin D (25(OH)D) levels between cities located at different altitudes:  
237 Among the participants from Quito, Ambato and Ibarra, 64.18% had inadequate  
238 levels, while 52.74% of the participants from Santo Domingo had inadequate levels  
239 (chi-square = 18.1854,  $p < 0.001$ ). These findings suggest that altitude may play a  
240 role in 25-hydroxyvitamin D (25(OH)D) status, as people residing at higher  
241 altitudes are more likely to have inadequate levels.

242 Regarding the evolution of concentration of 25-hydroxyvitamin D (25(OH)D) across  
243 years, (**S2Table**) provides an overview of 25-hydroxyvitamin D (25(OH)D) levels,  
244 suggestive toxicity, and inadequate levels in different years and age groups. In  
245 2018, a significant difference in the prevalence of deficiency was observed  
246 between age groups, with the highest proportion in children and adolescents  
247 (42.9%), followed by young adults (43.0%), middle-aged adults (20.4%) and older  
248 adults (33.0%). Similarly, in 2021 a significant difference was found, with the  
249 highest proportion of deficiency in children and adolescents (29.1%), followed by  
250 older adults (26.1%), young adults (28.0%) and middle-aged adults (21.6%).  
251 Regarding inadequate levels, the prevalence varied between years and age  
252 groups, with the highest figures being observed in 2021 (2,695) and in the group of  
253 middle-aged adults (1,099). Suggestive toxicity was identified in a small number of  
254 cases, mainly in older adults. In general, there was a significant association  
255 between the year and the prevalence of deficiency and inadequate levels of 25-  
256 hydroxyvitamin D (25(OH)D), indicating variations over time.

257 We can observe the trend of monthly average plasma of 25-hydroxyvitamin D  
258 (25OHD) concentration during the pre-pandemic and pandemic periods. During the

259 pandemic period, although the values of 25-hydroxyvitamin D (25OHD) remain  
260 inadequate, there is an evident increase in the monthly average concentration of  
261 25-hydroxyvitamin D (25OHD). It increases from 2.4 ng/mL in 2018 to 2022 (Figure  
262 1).



263

264 **Figure 1. Monthly mean 25-hydroxyvitamin D (25OHD) concentration pre-pandemic**  
265 **and pandemic period.**

266 The results of the regression analysis (**Table 2**) revealed that there was a  
267 statistically significant average monthly increase in 25-hydroxyvitamin D (25(OH)D)  
268 concentration of 0.133 units ( $p=0.006$ ). The period after March 2020, compared  
269 with the period before March 2020, was associated with a non-significant reduction  
270 in mean 25-hydroxyvitamin D (25(OH)D) concentration of 1.605 units ( $p=0.477$ ).  
271 However, the interaction between the period after March 2020 and time was not  
272 significant ( $p=0.909$ ), suggesting that there was no additional monthly change in  
273 25-hydroxyvitamin D (25(OH)D) concentration after March 2020 beyond the  
274 increase. overall monthly. The constant term indicated a significant baseline mean  
275 25-hydroxyvitamin D (25(OH)D) concentration of 24.004 units at the start of the

276 study ( $p < 0.001$ ). The general model explained approximately 40.28% of the  
 277 variation in the average monthly concentration of 25-hydroxyvitamin D (25(OH)D)  
 278 (R-squared=0.4028, R-squared=0.3629) and was statistically significant ( $F=10.12$ ,  
 279  $p < 0.001$ ).

280 **Table 2: Regression analysis of monthly average 25-hydroxyvitamin D (25(OH)D) concentration,**  
 281 **before and after March 2020.**

Variable	Coefficient		
	(Average Monthly 25-hydroxyvitamin D (25(OH)D) concentration)	t statistic	p-value
Time* (per each month)	0.133	2.90	0.006
Post-March 2020** (1)	-1.605	-0.72	0.477
Post-March 2020*Time***	0.008	0.11	0.909
Constant****	24.004	33.94	<0.001

\* The "Time" coefficient refers to the average monthly increase in 25-hydroxyvitamin D (25(OH)D) concentration across all participants in the study.  
 \*\* "Post-March 2020 (1)" is the average difference in 25-hydroxyvitamin D (25(OH)D) concentration for all months after March 2020 (the 27th month of the study), compared to the months before March 2020.  
 \*\*\* "Post-March 2020\*Time" is the interaction term, representing any additional monthly change in Vitamin D concentration after March 2020, beyond the general monthly increase.  
 \*\*\*\*The Constant term represents the average 25-hydroxyvitamin D (25(OH)D) concentration at the start of the study (Time = 0).

282

283 The proportion of toxicity across 2018 to 2021 increased significantly and the  
 284 inadequate levels of 25-hydroxyvitamin D (25(OH)D) reduces in the same period,  
 285 but with a non-significant change (**S3, S4 Tables**). These findings highlight the  
 286 presence of a general upward trend in 25-hydroxyvitamin D (25(OH)D)  
 287 concentration over time, but no additional significant monthly change after the  
 288 onset of the COVID-19 pandemic in March 2020. Results from the regression  
 289 model Poisson tests indicate a significant increase in the prevalence of toxicity  
 290 (**Table 3**) during the period from 2018 to 2021. Specifically, the prevalence of

291 toxicity was found to be 6.53 times higher in 2020 and 7.37 times higher in 2021  
292 compared to the base year 2018. In contrast, the prevalence of inadequate 25-  
293 hydroxyvitamin D (25(OH)D) levels (**Table 4**) showed a slight but not statistically  
294 significant decrease over the same period. The prevalence was found to be 3.5%  
295 lower in 2020 and 8% lower in 2021 compared to 2018. These findings suggest  
296 divergent trends in the two health outcomes over the study period.

297 **Table 3: Poisson Regression Results for Toxicity\* (2019-2021)**

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019	-0.5614968	1.414.213	-0.40	0.691	0.57
2020	1.876.703	1.027.402	1.83	0.068	6.53
2021**	1.997.484	1.013.072	1.97	0.049	7.37

\*Suggestive Toxicity was defined based on the presence of symptoms indicating potential harm or risk due to excess 25-hydroxyvitamin D (25(OH)D), as ascertained by medical evaluation, and when the concentration of 25-hydroxyvitamin D (25(OH)D) exceeded 100 ng/mL.

\*\*The positive coefficient suggests a positive relationship between the year 2021 and toxicity, the p-value < 0.05, indicating statistical significance.

298

299 **Table 4: Poisson Regression Results for Inadequate Vitamin D Level\* (2019-2021)**

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019**	0.0111135	0.0524749	0.21	0.832	1.01
2020**	-0.0359239	0.0492221	-0.73	0.465	0.965
2021**	-0.0830686	0.0461695	-1.80	0.072	0.92

\* Inadequate 25-hydroxyvitamin D (25(OH)D) Level was defined as having a concentration of 25-hydroxyvitamin D (25(OH)D) less than 20 ng/mL.

\*\* These results suggest that there is no strong and consistent evidence for significant changes in the prevalence of inadequate vitamin D levels across the years 2019, 2020, and 2021.

300

## 301 **Discussion**

### 302 *Main findings*

303 This study revealed a high prevalence of inadequate levels of 25-hydroxyvitamin D  
304 (25(OH)D) (64.58%) among individuals attending a private laboratory in Quito,

305 Ecuador. These findings align with a meta-analysis conducted between 2000 and  
306 2022, which estimated the global and regional prevalence of deficiency in serum  
307 25-hydroxyvitamin D levels. The meta-analysis included 308 studies with  
308 7,947,359 participants from 81 countries, finding that 15.7% had levels below 12  
309 ng/dL and 47.9% had levels below 20 ng/dL. Although the prevalence slightly  
310 decreased from 2000–2010 to 2011–2022, it remained at a high level[10].  
311 Similarly, another meta-analysis conducted in an Asian population, including  
312 746,564 subjects, reported that 22.82% had levels below 12 ng/dL and 57.69%  
313 had levels below 20 ng/dL, indicating a high prevalence of 25-hydroxyvitamin D  
314 (25(OH)D) deficiency in Asia. 25-hydroxyvitamin D (25(OH)D) levels varied based  
315 on gender, age group, region, altitude, and disease. Several factors contributed to  
316 these results, including dietary habits. Vitamin D is only present in a few foods,  
317 such as fish liver oil and fatty fish, which are not commonly consumed by Asians,  
318 especially central Asians. Additionally, Asians tend to prefer a lighter skin color,  
319 leading to the use of sunscreen and parasols outdoors, which reduces the  
320 penetration of ultraviolet B (UVB) and subsequently decreases vitamin D synthesis.  
321 Clothing habits also play a significant role, as many individuals in western and  
322 southern Asia, where Muslim populations reside, wear long robes and veils that  
323 cover the skin. Moreover, people living in southern and Southeast Asia generally  
324 have darker skin, which can block UVB penetration. Economic development also  
325 influences vitamin D levels, particularly in Asian countries that are still developing  
326 and lack access to effective vitamin D supplements[10].

327 Furthermore, another meta-analysis estimated the prevalence of 25-  
328 hydroxyvitamin D (25(OH)D) deficiency in Africa. This analysis included 119  
329 studies with 21,474 participants from 23 countries. The findings indicated that  
330 18.46% had values below 12 ng/dL and 34.22% had values below 20 ng/dL. The  
331 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency exhibited regional  
332 variation, with the highest rates observed in northern African countries and South  
333 Africa[11]. Among population subgroups, women, newborn babies, and urban  
334 populations had the lowest concentrations of 25(OH)D. Notably, populations living  
335 in urban areas exhibited lower 25(OH)D concentrations compared to rural

336 populations, potentially due to limited sunlight exposure duration or reduced dietary  
337 intake of vitamin D. Conversely, the populations in Africa that practiced traditional  
338 lifestyles, including nomadic animal rearing, hunting, and gathering, demonstrated  
339 the highest 25(OH)D concentrations[11].

340 In a meta-analysis that estimated the prevalence of 25-hydroxyvitamin D  
341 (25(OH)D) deficiency in South America, 96 studies with a total of 227,758  
342 participants were included from an initial pool of 9,460 articles. The overall  
343 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency, defined by a 25(OH)D  
344 concentration below 20 ng/mL, was found to be 34.76%. Lifestyle factors such as  
345 spending more time indoors for work, leisure, and physical activities, coupled with  
346 dietary patterns and public health campaigns that promote sunlight avoidance and  
347 skin protection, likely contribute to the lower-than-expected concentrations of  
348 25(OH)D in this region[5].

349 Ecuador, situated in the tropical zone, is longitudinally crossed by the Andes  
350 mountain range, which imparts distinct and prominent topographical characteristics  
351 throughout the country. The altitude of Ecuador's regions holds significant influence  
352 over various health outcomes experienced by its population[12]. Within the scope  
353 of this study, a pronounced disparity in inadequate 25-hydroxyvitamin D (25(OH)D)  
354 levels was observed in laboratory results obtained from individuals residing in  
355 Quito, positioned at an approximate elevation of 2,850 meters above sea level, in  
356 comparison to samples collected from individuals in Santo Domingo, situated at a  
357 lower altitude of approximately 625 meters above sea level. Upon comparing  
358 participants from Quito, Ambato, and Ibarra with those from Santo Domingo, it was  
359 found that 64.18% of individuals from higher-altitude cities exhibited inadequate  
360 25-hydroxyvitamin D (25(OH)D) levels, whereas the percentage was 52.74%  
361 among those from Santo Domingo. These findings indicate a potential correlation  
362 between altitude and 25-hydroxyvitamin D (25(OH)D) status, suggesting that  
363 individuals inhabiting higher altitudes are more susceptible to insufficient levels of  
364 this nutrient. Therefore, it is crucial to consider regional factors when evaluating 25-  
365 hydroxyvitamin D (25(OH)D) status and devising appropriate interventions. These



366 results align with other studies, including research conducted in Asia by Zhiwei  
367 Jiang, which revealed that individuals residing at lower altitudes ( $\leq 500$  m) tend to  
368 exhibit higher 25-hydroxyvitamin D (25(OH)D) levels compared to those at higher  
369 altitudes ( $> 500$  m)[10]. Furthermore, it has been observed that people living in  
370 high-altitude regions often encounter difficulties in accessing effective vitamin D  
371 supplements[10]. The studies conducted in South America have incorporated two  
372 fundamental factors, namely altitude and diet, into their analyses. At higher  
373 altitudes, the atmosphere is thinner, resulting in reduced absorption of ultraviolet  
374 radiation (UV levels increase by 10% to 12% with each 1000-meter increase in  
375 altitude)[5].

376 The findings of this study revealed a significant prevalence of inadequate 25-  
377 hydroxyvitamin D (25(OH)D) levels in the population, while the incidence of 25-  
378 hydroxyvitamin D (25(OH)D) toxicity was relatively low (0.62%). Interestingly,  
379 divergent changes were observed in these indicators during the study period.  
380 Although inadequate levels showed a non-significant reduction, there was a  
381 notable increase in the prevalence of toxicity from 2018 to 2021. These results  
382 underscore a concerning trend in the 25-hydroxyvitamin D (25(OH)D) status of the  
383 population. These findings are consistent with a study conducted in Ireland that  
384 aimed to investigate the impact of the COVID-19 pandemic on vitamin D status and  
385 the usage of newly introduced vitamin D supplements. A trend analysis based on  
386 laboratory data revealed a threefold rise in the yearly average of 25(OH)D during  
387 the initial year of the pandemic, compared to previous analyses. This trend  
388 suggests potential benefits for individuals with low vitamin D status but also  
389 highlights the risk for those with already high levels, especially considering the  
390 increasing availability of high-dose supplements[6].

391 The increased consumption of vitamin D supplements by the general population,  
392 including therapeutic and high-dose formulations, without adequate medical  
393 supervision, can significantly elevate the risk of exogenous hypervitaminosis D,  
394 commonly known as vitamin D toxicity. This condition can manifest symptoms of  
395 hypercalcemia[13]. Therefore, it is essential to ensure that the intake of vitamin D

396 is monitored by healthcare professionals to prevent overdosing and the associated  
397 severe health consequences[3,14,15].

398 Excessive intake of vitamin D can lead to the accumulation of the nutrient in the  
399 body for extended periods, up to 18 months, resulting in chronic toxic effects such  
400 as nephrocalcinosis, hypercalcemia, and hypercalciuria. In the past, fortification of  
401 foods, such as milk, was recommended as a public health strategy to prevent  
402 vitamin D deficiency and low 25-hydroxyvitamin D (25(OH)D) status. However,  
403 cases of increased hypercalcemia associated with excessive intake of fortified  
404 foods have been reported[3,14,15].

405 During the pandemic, there was a notable interest in studying the relationship  
406 between 25-hydroxyvitamin D (25(OH)D) levels and COVID-19. A study aimed at  
407 identifying if online search interest in vitamin D increased with the pandemic  
408 burden and analyzing the accuracy of public health messaging regarding vitamin D  
409 in online news articles found that a significant number of articles provided  
410 conflicting information or incorrectly advised supratherapeutic doses. This study  
411 emphasizes the opportunity for public health organizations to capitalize on the  
412 increased interest in vitamin D during the pandemic and disseminate accurate  
413 information to raise awareness[16].

414 However, it is important to acknowledge the limitations of this study. Important  
415 factors such as skin pigmentation, socioeconomic conditions, diet, sun exposure  
416 habits, cultural practices, and skin coverage with clothing were not considered in  
417 the analysis. These factors can influence 25-hydroxyvitamin D (25(OH)D) levels  
418 and should be considered in future research.

419 The results of this study reveal a high prevalence of 25-hydroxyvitamin D  
420 (25(OH)D) deficiency, indicating the need for strategies to prevent deficiency.  
421 However, the increase in toxicity also raises concerns and highlights the  
422 importance of rational prescribing of vitamin D supplements and educating the  
423 population to avoid self-medication. To optimize resource allocation and prioritize  
424 those at higher risk, it may be beneficial to focus vitamin D testing on specific

425 populations. Individuals with malabsorption syndromes, individuals undergoing  
426 steroid therapy, or older adults who are confined to their homes are examples of  
427 higher-risk groups. Assessing serum of 25-hydroxyvitamin D (25(OH)D) levels in  
428 these cases can provide valuable clinical insights and inform appropriate  
429 interventions.

## 430 **Supporting Information**

431 ***S1 Table: Prevalence of inadequate levels of Vitamin D among: (i) those who does not have self-***  
432 ***reported diseases, (ii) those who are not taking medications, (iii) those who have reported any***  
433 ***chronic disease, and (iv) those who are taking any medication.***

<b>Variable</b>	<b>n=919</b>
No self-reported diseases, <i>n (%)</i>	399 (63)
No medications, <i>n (%)</i>	471 (64)
Any self-reported disease, <i>n (%)</i>	181 (64)
Any medication, <i>n (%)</i>	109 (61)

Inadequate levels were defined as a 25-hydroxyvitamin D (25(OH)D) concentration below 20 ng/mL.

434 **S2 Table: 25-hydroxyvitamin D (25(OH)D) levels, suggestive toxicity, and inadequate levels per year and age group.**

Year	25-hydroxyvitamin D (25(OH)D)	Age ranges							
		1-2 (n=34)	3-5 (n=93)	6-11 (n=275)	12-17 (n=440)	18-65 (n=5630)	66-79 (n=1685)	80-99 (n=1070)	>99 (n=14)
2018	Mean concentration in ng/mL, mean (SD)	-	19.4 (8.0)	24.1 (17.0)	21.8 (10.9)	26.4 (12.0)	26.6 (10.4)	22.3 (9.6)	12.2 (4.6)
	Inadequate levels, <i>n (%)</i> *	-	11 (58)	27 (44)	38 (45)	311 (72)	93 (69)	78 (85)	3 (100)
	Suggestive of toxicity, <i>n (%)</i> **	-	-	1 (2)	-	-	-	-	-
2019	Mean concentration in ng/mL, mean (SD)	-	30.5 (10.7)	28.4 (6.9)	27.7 (10.7)	26.3 (10.8)	25.9 (11.0)	24.3 (12.6)	-
	Inadequate levels, <i>n (%)</i> *	-	9 (39)	2 (5)	11 (19.7)	677 (71.9)	206 (76.0)	96 (76.8)	-
	Suggestive of toxicity, <i>n (%)</i> **	-	-	-	-	1 (0.1)	-	-	-
2020	Mean concentration in ng/mL, mean (SD)	23.8 (13.4)	30.2 (16.3)	29.5 (15.3)	22.9 (8.6)	27.5 (14.4)	30.1 (17.6)	24.2 (16.7)	8 (-)
	Inadequate levels, <i>n (%)</i> *	4 (50)	2 (13)	11 (19)	34 (40)	989 (67)	255 (65)	202 (79)	2 (100)
	Suggestive of toxicity, <i>n (%)</i> **	-	-	1 (2)	-	10 (1)	4 (1)	3 (1)	-
2021	Mean concentration in ng/mL, mean (SD)	30.6 (12.6)	32.6 (10.2)	27.2 (11.0)	23.6 (10.9)	29.1 (14.7)	29.7 (16.2)	24.8 (15.5)	17.0 (12.6)
	Inadequate levels, <i>n (%)</i> *	5 (20)	-	25 (23)	79 (39)	1646 (65)	500 (62)	427 (77)	8 (89)
	Suggestive of toxicity**	-	-	-	1 (1)	21 (1)	10 (1)	6 (1)	-
2022	Mean concentration in ng/mL, mean (SD)	21.7 (-)	17.2 (10.6)	24.1 (6.4)	20.7 (6.8)	30.1 (11.6)	29.4 (9.8)	27.3 (15.7)	-
	Inadequate levels, <i>n (%)</i> *	-	1 (50)	3 (27.2)	4 (40)	138 (58)	45 (62)	26 (60)	-
	Suggestive of toxicity, <i>n (%)</i> **	-	-	-	-	-	-	-	-

\* Inadequate levels" when the values were; for children <20 ng/ml; for young adults <30 ng/ml; for pregnant women <20 ng/ml; and, for elderly people <30 ng/ml  
 \*\* 'Suggestive of toxicity' of vitamin D are not represented in this table. Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.

435 **S3 Table: Annual Prevalence Rates of Vitamin D Toxicity (%).**

Year	n	Prevalence Rate (%)	95% Confidence Interval
2018	835	0.12	0.02 - 0.85
2019	1464	0.07	0.01 - 0.48
2020	2301	0.78	0.49 - 1.24
2021	4305	0.88	0.64 - 1.21

Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.

436

437 **S4 Table: Proportion of patients with inadequate vitamin D levels per year**

Año	n	Proporción	Intervalo de confianza del 95%
2018	835	0.68	0.65 - 0.71
2019	1464	0.69	0.66 - 0.71
2020	2301	0.66	0.64 - 0.68
2021	4305	0.63	0.61 - 0.64

Less than 20 ng/ml for general population and less than 30 ng/ml for older adults and pregnant women

438

439 **Footnotes:**

440 **Acknowledgment:** The authors express their sincere appreciation to the  
441 healthcare professionals at Zurita & Zurita Laboratories for their expert handling of  
442 the samples, which significantly contributed to the accuracy of our study.  
443 Furthermore, ChatGPT from OpenAI was utilized to improve the document's overall  
444 writing quality. No AI was involved in the study design, data analysis, interpretation  
445 or substantial writing and reviewing of the manuscript.

446 **Funding statement:** This research received no specific grant from any funding  
447 agency in the public, commercial or not-for-profit sectors.

448 **Author Contributions**

449 Conceptualization: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín

450 Data curation: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas

451 Formal analysis: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas

452 Investigation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete  
453 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José  
454 Pareja-Maldonado.

455 Methodology: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín

456 Validation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete  
457 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José  
458 Pareja-Maldonado.

459 Writing – original draft: Betzabé Tello, Iván Dueñas-Espín

460 Writing – review & editing: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-  
461 Espín, Jeannete Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-  
462 Muñoz , José Pareja-Maldonado.

463 Declaration of interest: None

464 **Patient consent for publication:** Not required.

465 **Data-sharing statement:** Data are available upon reasonable request. All data  
466 relevant to the study were included in the article.

467 **Ethics approval:** The study protocol (CEISH 659-2022) received ethical approval  
468 from the Ethics Committee for Research in Human Beings of the Pontifical Catholic  
469 University of Ecuador, following an expedited review process.

## 470 **References**

471 1 Cashman KD. Vitamin D Deficiency: Defining, Prevalence, Causes, and  
472 Strategies of Addressing. *Calcif. Tissue Int.* 2020;**106**:14–29.  
473 doi:10.1007/s00223-019-00559-4

474 2 Melmed S, Auchus R, Goldfi A, *et al.* *Williams. Tratado de endocrinología.*  
475 14.<sup>a</sup> edici. España: 2021.

- 476 3 Gallagher JC, Rosen CJ. Vitamin D: 100 years of discoveries, yet  
477 controversy continues. *lancet Diabetes Endocrinol* 2023;**11**:362–74.  
478 doi:10.1016/S2213-8587(23)00060-8
- 479 4 Cui A, Zhang T, Xiao P, *et al.* Global and regional prevalence of vitamin D  
480 deficiency in population-based studies from 2000 to 2022: A pooled analysis  
481 of 7.9 million participants. *Front Nutr* 2023;**10**.  
482 doi:10.3389/fnut.2023.1070808
- 483 5 Mendes M, Gomes A, Araújo M, *et al.* Prevalence of vitamin D deficiency in  
484 South America: A systematic review and meta-analysis. *Nutr Rev* Published  
485 Online First: 2023. doi:10.1093/nutrit/nuad010
- 486 6 Mckenna MJ, Lyons OC, Flynn MAT, *et al.* COVID-19 pandemic and vitamin  
487 D: rising trends in status and in daily amounts of vitamin D provided by  
488 supplements. *BMJ Open* 2022;**12**:1–8. doi:10.1136/bmjopen-2021-059477
- 489 7 Rustecka A, Maret J, Drab A, *et al.* The impact of covid-19 pandemic during  
490 2020–2021 on the vitamin d serum levels in the paediatric population in  
491 warsaw, poland. *Nutrients* 2021;**13**. doi:10.3390/nu13061990
- 492 8 Ruiz-garc A, Pallar V, Tur M, *et al.* Vitamin D Supplementation and Its Impact  
493 on Mortality and Cardiovascular Outcomes: Systematic Review and.  
494 2023;;1–16.
- 495 9 Berger MM, Shenkin A, Schweinlin A, *et al.* ESPEN micronutrient guideline.  
496 *Clin Nutr* 2022;**41**:1357–424. doi:10.1016/j.clnu.2022.02.015
- 497 10 Cui X, Zhai Y, Wang S, *et al.* Effect of the COVID-19 Pandemic on Serum  
498 Vitamin D Levels in People under Age 18 Years: A Systematic Review and  
499 Meta-Analysis. *Med Sci Monit* 2022;**28**:1–9. doi:10.12659/MSM.935823
- 500 11 Mogire RM, Mutua A, Kimita W, *et al.* Prevalence of vitamin D deficiency in  
501 Africa: a systematic review and meta-analysis. *Lancet Glob Heal*  
502 2020;**8**:e134–42. doi:10.1016/S2214-109X(19)30457-7



- 503 12 Robles Rodríguez JB, Pazmiño K, Jaramillo A, *et al.* Relación entre  
504 deficiencia de vitamina D con el estado nutricional y otros factores en  
505 adultos de la región interandina del Ecuador. *Perspect en Nutr Humana*  
506 2022;**24**:35–48. doi:10.17533/udea.penh.v24n1a03
- 507 13 Muneer S, Siddiqui I, Majid H, *et al.* Practices of vitamin D supplementation  
508 leading to vitamin D toxicity: Experience from a Low-Middle Income Country.  
509 *Ann Med Surg* 2022;**73**:103227. doi:10.1016/j.amsu.2021.103227
- 510 14 Amrein K, Scherkl M, Hoffmann M, *et al.* Vitamin D deficiency 2.0: an update  
511 on the current status worldwide. *Eur J Clin Nutr* 2020;**74**:1498–513.  
512 doi:10.1038/s41430-020-0558-y
- 513 15 Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiwicz J, *et al.*  
514 Vitamin D Toxicity a clinical perspective. *Front Endocrinol (Lausanne)*  
515 2018;**9**:1–7. doi:10.3389/fendo.2018.00550
- 516 16 Heer RS, Sandhu P, Wenban C, *et al.* Vitamin D in the news: A call for clear  
517 public health messaging during Covid-19. *Nutr Health* 2022;**28**:733–9.  
518 doi:10.1177/02601060221090293
- 519